Unicycive Therapeutics (Nasdaq: UNCY) announced that CEO Shalabh Gupta, M.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 11 a.m. ET. A live and archived webcast will be available via the Investors section of the Unicycive website.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The 3.1% reaction to news_id 1037606 provides a conference-announcement comparison for this scheduli...
Analysis
The 3.1% reaction to news_id 1037606 provides a conference-announcement comparison for this scheduling update. The platform record adds historical context, while the active S-3 registration and moderate short positioning remain relevant risks to monitor.
NDA resubmission acceptance and potential third-quarter commercial launch were announced
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Historical reactions were mixed: the FDA complete response letter aligned with a sharp decline, while earnings and conference updates produced divergent moves.
Key Terms
hyperphosphatemia, orphan drug designation, delayed graft function, dose-ranging safety study
4 terms
hyperphosphatemiamedical
"for the treatment of hyperphosphatemia in patients with chronic kidney disease"
An elevated level of phosphate in the blood, often caused by reduced kidney function or certain medications, that can harm bones, blood vessels and organs if untreated. Investors should care because prevalence, safety concerns and regulatory scrutiny around treatments or diagnostics for this condition can drive demand, affect clinical trial outcomes, influence healthcare spending and change a company’s revenue and risk profile—similar to how a common road hazard can change demand for safety products.
orphan drug designationregulatory
"It has been granted orphan drug designation (ODD) by the FDA"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
delayed graft functionmedical
"for the prevention of Delayed Graft Function (DGF) in kidney transplant patients"
Delayed graft function is when a transplanted organ—most commonly a kidney—does not start working right away after surgery, usually identified by the need for dialysis within the first week or by very low urine output. It matters to investors because it is a common clinical outcome used to measure transplant success, influences short-term hospital costs, patient recovery time, and can affect longer-term graft survival and regulatory or trial results.
dose-ranging safety studymedical
"has completed a Phase 1 dose-ranging safety study in healthy volunteers"
A dose-ranging safety study is an early-stage clinical trial that tests several different doses of an investigational drug to find how much can be given safely and what side effects appear at each level. It matters to investors because these studies shape later trial design and regulatory chances—like a thermostat test that finds safe temperature ranges before running a full-scale system, their results influence development cost, timeline, and risk.
LOS ALTOS, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 11 a.m. ET.
A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.
When will Unicycive Therapeutics (UNCY) present at the H.C. Wainwright 28th Annual Global Investment Conference in 2026?
Unicycive Therapeutics will present on Tuesday, September 15, 2026, at 11 a.m. ET. According to Unicycive, CEO Shalabh Gupta, M.D., will deliver the presentation as part of the H.C. Wainwright 28th Annual Global Investment Conference.
How can investors access the Unicycive Therapeutics (UNCY) webcast for the H.C. Wainwright 2026 conference presentation?
Investors can access the live and archived webcast through the Unicycive website’s Investors > Events and Presentations section. According to Unicycive, the link will provide both real-time viewing and later on-demand access for interested stakeholders.
What is Unicycive Therapeutics’ lead investigational treatment mentioned ahead of the September 15, 2026 UNCY presentation?
Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate-binding agent. According to Unicycive, it is being developed to treat hyperphosphatemia in chronic kidney disease patients who are on dialysis, targeting phosphate control in this population.
What is UNI-494 in Unicycive Therapeutics’ (UNCY) pipeline and what stage is it in?
UNI-494 is Unicycive’s second investigational treatment intended for conditions related to acute kidney injury. According to Unicycive, UNI-494 has FDA orphan drug designation for preventing delayed graft function and has completed a Phase 1 dose-ranging safety study in healthy volunteers.
Does UNI-494 from Unicycive Therapeutics (UNCY) have FDA orphan drug designation and for what indication?
Yes, UNI-494 has FDA orphan drug designation for preventing delayed graft function in kidney transplant patients. According to Unicycive, this investigational therapy targets complications related to acute kidney injury in the transplant setting.
What disease areas is Unicycive Therapeutics (UNCY) focused on as it presents at the 2026 H.C. Wainwright conference?
Unicycive focuses on developing novel treatments for kidney diseases, including chronic and acute conditions. According to Unicycive, its pipeline includes oxylanthanum carbonate for hyperphosphatemia in dialysis patients and UNI-494 for conditions related to acute kidney injury in transplant settings.
